MTEM - Molecular Templates Inc Stock Price, Fair Value and News

$0.16-0.19 (-54.29%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MTEM Price Action

Last 7 days

-60%

Last 30 days

-59.0%

Last 90 days

-88.1%

Trailing 12 Months

-95.7%

MTEM RSI Chart

MTEM Valuation

Market Cap

1.1M

Price/Earnings (Trailing)

-0.07

Price/Sales (Trailing)

0.04

EV/EBITDA

-30.05

Price/Free Cashflow

-0.04

MTEM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MTEM Fundamentals

MTEM Revenue

Revenue (TTM)

25.5M

Rev. Growth (Yr)

-91.67%

Rev. Growth (Qtr)

-94.84%

MTEM Earnings

Earnings (TTM)

-15.6M

Earnings Growth (Yr)

25.5%

Earnings Growth (Qtr)

-1.5K%

MTEM Profitability

EBT Margin

-31.94%

Return on Equity

-219.74%

Return on Assets

-58.53%

Free Cashflow Yield

-2.3K%

MTEM Investor Care

Shares Dilution (1Y)

22.51%

Diluted EPS (TTM)

-0.56

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	31.8M	25.5M	0	0
2023	47.9M	50.3M	52.9M	57.3M
2022	44.0M	33.2M	35.1M	19.8M
2021	17.9M	26.1M	24.2M	38.7M
2020	19.4M	20.9M	21.5M	18.8M
2019	19.8M	23.9M	20.8M	22.3M
2018	2.0M	3.3M	9.4M	13.3M
2017	2.3M	2.6M	3.0M	3.4M
2016	0	0	39.4M	1.9M
2015	14.7M	14.7M	14.7M	76.9M
2014	13.3M	13.8M	14.3M	14.7M
2013	8.5M	9.9M	11.3M	12.5M
2012	1.3M	2.6M	3.9M	5.9M
2011	0	0	0	62.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

CEO	Dr. Eric E. Poma Ph.D.
WEBSITE	mtem.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	111

Molecular Templates Inc Frequently Asked Questions

What is the ticker symbol for Molecular Templates Inc? What does MTEM stand for in stocks?

MTEM is the stock ticker symbol of Molecular Templates Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Molecular Templates Inc (MTEM)?

As of Fri Dec 20 2024, market cap of Molecular Templates Inc is 1.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MTEM stock?

You can check MTEM's fair value in chart for subscribers.

Is Molecular Templates Inc a good stock to buy?

The fair value guage provides a quick view whether MTEM is over valued or under valued. Whether Molecular Templates Inc is cheap or expensive depends on the assumptions which impact Molecular Templates Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MTEM.

What is Molecular Templates Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, MTEM's PE ratio (Price to Earnings) is -0.07 and Price to Sales (PS) ratio is 0.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MTEM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Molecular Templates Inc's stock?

In the past 10 years, Molecular Templates Inc has provided -0.551 (multiply by 100 for percentage) rate of return.